Skip to main content
Premium Trial:

Request an Annual Quote

Vin Miles, Jeff Vick, Iain Ross, Jeremy Curnock Cook

Premium
Dicerna Pharmaceuticals said this week that Vin Miles has joined its board of directors.
 
Miles is currently a venture partner at life sciences investment group Abingworth. Prior to this, he served as senior vice president of business development for RNAi drug shop Alnylam Pharmaceuticals.
 
Abingworth was an early investor in Alnylam.
 
“Miles’ deep operating experience in the biotechnology industry and familiarity with RNAi is a tremendous asset and complement to our existing capabilities,” Dicerna CEO and Co-founder Jim Jenson said in a statement.
 

 
Silence Therapeutics said this week that CEO Jeff Vick has resigned for “personal reasons.”
 
The company said its board has now appointed Iain Ross, non-executive chairman, as the full-time chairman and CEO.
 
Silence also said that Jeremy Curnock Cook, a non-executive director, has been named senior independent non-executive director.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.